الانتقال إلى المحتوى الرئيسي
xMedica

NCT07516444ClinicalTrials.gov

VDyne TriNova Transcatheter Tricuspid Valve Replacement Study to Evaluate Safety and Clinical Efficacy in Patients With Symptomatic Severe Tricuspid Valve Regurgitation (TRIVITA Pivotal Trial)

VDyne Transcatheter Tricuspid Valve Replacement Study to Evaluate Safety and Clinical Efficacy in Patients With Symptomatic Severe Tricuspid Valve Regurgitation

قيد التجنيديقبل مشاركين الآن، وفقاً لسجل السجل.
التواصل مع هذه الدراسة

باختصار

Pivotal trial to evaluate the safety and clinical efficacy of the VDyne TriNova System for the treatment of symptomatic severe or greater tricuspid regurgitation.

تدخّليةمطلوب 520 مشاركاً12 موقعاًدولة واحدة

الفئات

مسجَّلة في سجل واحد

يمكن أن تُسجَّل دراسة واحدة في عدة سجلات. نعرضها مرة واحدة ونربط بكل سجل نحتفظ به.

تُعرض معلومات التجربة كما نشرها السجل، بلغتها الأصلية.

هل أنت مهتم بهذه الدراسة؟

تسجيل الدخول أو أنشئ حسابًا لتسجيل اهتمامك ومتابعة هذه الدراسة.

How this study is set up

The points below are drawn from the public registry record for this study. Each one cites the field or sentence it came from. A dash (—) means the record does not state something — not that it is missing or wrong. Many well-run studies, especially small ones, leave some of these blank.

  • Present: Registered before enrolment beganFirst posted 2026-04-08; recorded start 2026-07-28
  • Present: Has a defined primary outcomeA primary outcome measure is listed in the record
  • Present: The primary outcome states a time frameThe primary outcome measure records a time frame
  • Present: Participants are randomly assignedAllocation is recorded as randomised
  • Present: Has a comparison groupThe record lists a placebo or comparator arm, or more than one study arm
  • Present: Uses blinding (masking)A masking level is recorded in the record
  • Not stated: An ethics committee is not stated in the registry recordThis registry's ingested record has no ethics-committee field
  • Not stated: Regulatory oversight (such as an IND or IDE) is not stated in the registry recordThis registry's ingested record has no regulatory-authorisation field
  • Not stated: A data monitoring committee is not stated in the registry recordThis registry's ingested record has no data-monitoring-committee fieldA data monitoring committee is not required for many smaller studies, and its absence here is not unusual.
  • Present: No cost to participants is mentioned in the recordChecked the summary, description and eligibility text; no cost-to-participant phrase found
  • Present: Sponsor has 2 other studies in this databaseCounted from the lead sponsor named in the record (VDyne, Inc.)
  • Not stated: No posted results from this sponsor are in this database yetBased on the sponsor’s studies in this database
  • The record lists 8 conditions.
  • Lead sponsor type recorded as: industry.

Trial stature

Three independent measures of this study, described from its registry record — not a recommendation about it. A rigorous study by investigators nobody has heard of is better evidence than a weak study led by a famous one. How these are scored.

Methodological rigourSTRONG

A strong methodological design for a study of this type, judged from its ClinicalTrials.gov record.

How this score is built
  • Randomised allocation20/20

    Participants are randomly allocated between arms

  • Blinding7/20

    Single-blind

  • Control arm15/15

    Active-comparator control arm

  • Primary-outcome specificity10/10

    Named primary outcome with a defined time frame

  • Endpoint type3/10

    Surrogate or intermediate endpoint (conservative default)

  • Multi-centre0/8

    Single site, or site count not stated

  • Data monitoring committee7/7

    A data monitoring committee is in place

  • Prospective registration5/5

    Registered before the study start date

  • Protocol / SAP posted0/5

    No protocol or SAP posted to the registry

ScaleMEDIUM

A medium-sized study: 520 participants (target), run at 12 sites.

How this score is built
  • Enrolment28/40

    730 participants (target)

  • Site count0/25

    Site count not stated in the record

  • Country count0/15

    Country count not stated in the record

  • Planned duration10/10

    Planned over about 122 months

  • Sponsor scale1/10

    VDyne, Inc. has led 3 trials in our corpus

Investigator standingUNKNOWN

We have no verifiable track record for the investigator named on this trial. That is common for early-career investigators and for records held outside ClinicalTrials.gov — it is not a negative signal.

How this score is built
  • Investigator standing0/100

    No investigator recorded in the registry for this trial

These describe the registry record only, and today we hold ClinicalTrials.gov data. Absent fields lower a score, and absence often reflects registration practice rather than study quality. A high-stature trial is not necessarily safer or a better choice for you — enrolling in a large definitive trial can mean a higher chance of receiving placebo, while a small early-phase study may be the only route to a new therapy.

ملخص

Pivotal trial to evaluate the safety and clinical efficacy of the VDyne TriNova System for the treatment of symptomatic severe or greater tricuspid regurgitation.

The clinical trial is a prospective, multi-center, randomized controlled pivotal trial to evaluate the safety and effectiveness of the VDyne TriNova Transcatheter Tricuspid Valve Replacement (TTVR) System compared to Edwards EVOQUE TTVR System in symptomatic patients with severe or greater tricuspid regurgitation. Subjects will be followed at discharge, 30 days, 3 months, 6 months and annually through 5 years.

الحالات

  • Tricuspid Valve Regurgitation
  • Tricuspid Valve Disease
  • Cardiovascular Diseases (CVD)
  • Heart Valve Diseases
  • Tricuspid Valve Insufficiency
  • Severe Heart Valve Disease
  • Randomized Controlled Trial (RCT)
  • Symptomatic Tricuspid Regurgitation

الأهلية

الأهلية
الجنسالجميع
الأعمار18 Years – لا حد أقصى
المتطوعون الأصحّاءلا

الأهلية كما كُتبت في السجل

Inclusion Criteria: * Age ≥18 years old * Subject is willing and able to comply with all study evaluations and provide consent * Subject must agree not to participate in any other clinical trial for a period of one year following index procedure * New York Heart Association (NYHA) Functional Class II, III, or IV and ambulatory * At least severe symptomatic tricuspid regurgitation. * Despite adequate and Optimized Medical Therapy (OMT), subject has signs and symptoms from TR, or prior heart failure hospitalization from TR * Heart team determines that the subject is appropriate for transcatheter tricuspid valve replacement * Functional and/or degenerative TR graded as at least severe Exclusion Criteria: * Subject unable or unwilling to comply with study required testing and follow-up visits * Subject is currently participating in another clinical trial (drug, biologic, or device) that has not yet completed its primary endpoint or is likely to interfere with this study * Pregnant, lactating subjects, and /or those who plan pregnancy in the period up to one year following index procedure. * Known hypersensitivity or contraindication to procedural or post-procedural medications (e.g., contrast solution, anticoagulation, etc.) which cannot be adequately managed medically * Life expectancy ≤12 months due to non-cardiac comorbidities * Current IV Drug user (must be free from drug abuse for ≥1 year) * Subject unable or unwilling to provide written, informed consent before study enrollment * Tricuspid valve anatomy (cardiac and vascular) that is not suitable for the VDyne System * Hypersensitivity to metals (such as nickel or titanium) * Prior tricuspid valve surgery or catheter-based therapy with permanent residual device(s) implanted that would preclude delivery or implantation of the VDyne valve (e.g., valve replacement, edge to edge repair, etc.) * Severe valvular heart disease using established echocardiographic criteria requiring intervention other than the tricuspid valve * Known significant intracardiac shunt (e.g., septal defect). * Cerebrovascular accident (stroke, TIA) within 90 days of treatment procedure * Severe lung disease (severe COPD) or continuous use of home oxygen or oral steroids * Acute myocardial infarction (AMI) within 30 days of SSC determination of eligibility * Leukopenia, chronic anemia (Hgb \< 9 g/dL), current thrombocytopenia (platelets \<70/mcL), history of bleeding diathesis, or coagulopathy * Unwilling to receive blood products * Deep vein thrombosis and/or pulmonary embolism in the last 6-months

الأهلية في عبارات بسيطة

لم تُقسَّم معايير هذا السجل إلى عبارات منفصلة بعد. نص السجل أعلاه كامل وهو النسخة المُعتمَدة.

تصميم الدراسة

تصميم الدراسة
نوع الدراسةتدخّلية
المرحلةغير منطبق
التخصيصمعشّاة
نموذج التدخّلPARALLEL
الغرض الأساسيTREATMENT
التعميةSINGLE (1)
التجنيدمطلوب 520 مشاركاً

الجهة الراعية والمتعاونون

  • VDyne, Inc. الجهة الراعية

الأذرع والتدخلات

  • Randomized cohort VDyne TriNova TTVREXPERIMENTAL

    Transcatheter tricuspid valve replacement with VDyne TriNova System in patients with severe or greater tricuspid regurgitation.

  • Randomized cohort Edwards EVOQUE TTVRACTIVE_COMPARATOR

    Transcatheter tricuspid valve replacement with Edwards EVOQUE System in patients with severe or greater tricuspid regurgitation.

  • Single Arm RegistryEXPERIMENTAL

    Transcatheter tricuspid valve replacement with VDyne TriNova System in patients with severe or greater tricuspid regurgitation who are deemed ineligible to be treated with Active Comparator EVOQUE device.

التدخلات

  • جهاز Transcatheter Tricuspid Valve Replacement (TTVR) with Edwards EVOQUE System

    Subjects will undergo TTVR procedure with Edwards EVOQUE device and will continue to be managed on Optimal Medical Therapy (OMT).

  • جهاز Transcatheter Tricuspid Valve Replacement (TTVR) with VDyne TriNova System

    Subjects will undergo TTVR procedure with VDyne TriNova device and will continue to be managed on Optimal Medical Therapy (OMT).

مقاييس النتائج

  1. مقياس النتيجة الأولي

    Composite of major adverse events (MAEs)

    * Cardiovascular mortality * Myocardial infarction * All stroke * New need for renal replacement therapy * Severe bleeding * Non-elective tricuspid valve re-intervention * Major access site and vascular complications * Major cardiac structural complications * Device-related pulmonary embolism * New arrhythmia or conduction disorder requiring permanent pacing

    الإطار الزمني 30 days post-procedure

  2. مقياس النتيجة الأولي

    Composite of all-cause mortality, heart failure hospitalization, or non-elective tricuspid valve reintervention

    الإطار الزمني 12 months post-procedure

  3. مقياس النتيجة الأولي

    Change in Quality of Life (QOL) as measured by Kansas City Cardiomyopathy Questionnaire (KCCQ)

    Quality of Life KCCQ questionnaire is a measure of health-related quality of life. It is a 23-item, self-administered instrument that quantifies physical function, symptoms (frequency, severity and recent change), social function, self-efficacy and knowledge, and quality of life related to Heart Failure. From 23-items, the Overall Summary Score (OSS) will be calculated. In the OSS, each of the 23 items are converted onto a 0 to 100 scale using this formula: (Raw score - Minimum Raw Score)/(Maximum Raw Score - Minimum Raw Score) \* 100. Then these are averaged across the 23 items. A score of 100 (the maximum score) would indicate maximum quality of life relating to heart failure and a score of 0 (scale minimum) would indicate the worst possible quality of life relating to heart failure, with higher scores generally indicating higher quality of life.

    الإطار الزمني 12 months post-procedure

  4. مقياس النتيجة الأولي

    Change in Quality of Life (QOL) as measured by New York Heart Association (NYHA)

    New York Heart Association (NYHA) Classification at 6 months. The New York Heart Association (NYHA) Classification provides a way of classifying the extent of heart failure by classifying patients in one of four categories based on their limitations during physical activity and in degree of shortness of breath and or angina pain. Class I is the least severe and Class IV is the most severe. The classes are: Class I - No symptoms and no limitation in ordinary physical activity, e.g. shortness of breath when walking, climbing stairs etc. Class II - Mild symptoms (mild shortness of breath and/or angina) and slight limitation during ordinary activity. Class III - Marked limitation in activity due to symptoms, even during less-than-ordinary activity, e.g. walking short distances. Comfortable only at rest. Class IV - Severe limitations. Experiences symptoms even while at rest. Mostly bedbound patients.

    الإطار الزمني 12 months post-procedure

  5. مقياس النتيجة الثانوي

    All-Cause Mortality

    Total number of deaths from any cause

    الإطار الزمني At 12 months and 24 months

  6. مقياس النتيجة الثانوي

    RVAD implantation or heart transplant

    Total number of patients requiring Right Ventricular Assist Device (RVAD) implantation or heart transplant

    الإطار الزمني At 12 months and 24 months

  7. مقياس النتيجة الثانوي

    Tricuspid valve surgical or percutaneous intervention

    Total number of non-elective tricuspid valve re-interventions

    الإطار الزمني At 12 months and 24 months

  8. مقياس النتيجة الثانوي

    Heart failure hospitalizations

    Total number of patients with at least one hospital admission due to heart failure

    الإطار الزمني At 12 months and 24 months

  9. مقياس النتيجة الثانوي

    Change in 6-Minute Walk Distance (6MWD)

    Functional status improvement, as measured by 6-Minute Walk Test total distance walked. The 6-Minute Walk Test (6MWT) is a test that measures the total distance an individual can walk on a flat, hard surface in 6 minutes. It is commonly used to evaluate functional exercise capacity in patients with conditions including heart failure. The minimum score possible is 0, which would represent an inability to walk any distance. There is no maximum score, as a patient could theoretically walk any distance in 6 minutes though 800 meters considered the top reference range, which is what would be expected by elite athletes. Higher score indicate greater higher exercise capacity and lower scores indicate lower exercise capacity.

    الإطار الزمني At 12 months and 24 months

  10. مقياس النتيجة الثانوي

    Change in Echocardiographic Tricuspid Regurgitation (TR) grade from baseline using TransThoracic Echocardiogram (TTE)

    Change in Tricuspid Regurgitation (TR) grade from baseline is measured. A 5-tier grading scheme will be used: mild, moderate, severe, massive and torrential. The change in TR grade is assessed using TransThoracic Echocardiogram (TTE) imaging.

    الإطار الزمني At 6 months, 12 months and 24 months post-implant compared to baseline

  11. مقياس النتيجة الثانوي

    Change in Quality of Life (QOL) as measured by New York Heart Association (NYHA)

    New York Heart Association (NYHA) Classification at 6 months. The New York Heart Association (NYHA) Classification provides a way of classifying the extent of heart failure by classifying patients in one of four categories based on their limitations during physical activity and in degree of shortness of breath and or angina pain. Class I is the least severe and Class IV is the most severe. The classes are: Class I - No symptoms and no limitation in ordinary physical activity, e.g. shortness of breath when walking, climbing stairs etc. Class II - Mild symptoms (mild shortness of breath and/or angina) and slight limitation during ordinary activity. Class III - Marked limitation in activity due to symptoms, even during less-than-ordinary activity, e.g. walking short distances. Comfortable only at rest. Class IV - Severe limitations. Experiences symptoms even while at rest. Mostly bedbound patients.

    الإطار الزمني 12 months post-procedure

  12. مقياس النتيجة الثانوي

    Change in Quality of Life (QOL) as measured by Kansas City Cardiomyopathy Questionnaire (KCCQ)

    Quality of Life KCCQ questionnaire is a measure of health-related quality of life. It is a 23-item, self-administered instrument that quantifies physical function, symptoms (frequency, severity and recent change), social function, self-efficacy and knowledge, and quality of life related to Heart Failure. From 23-items, the Overall Summary Score (OSS) will be calculated. In the OSS, each of the 23 items are converted onto a 0 to 100 scale using this formula: (Raw score - Minimum Raw Score)/(Maximum Raw Score - Minimum Raw Score) \* 100. Then these are averaged across the 23 items. A score of 100 (the maximum score) would indicate maximum quality of life relating to heart failure and a score of 0 (scale minimum) would indicate the worst possible quality of life relating to heart failure, with higher scores generally indicating higher quality of life.

    الإطار الزمني 12 months post-procedure

التواريخ

التواريخ
تاريخ البدء28 يوليو 2026 (فعلي)
الإتمام الأولي1 يونيو 2029 (تقديري)
الإتمام1 يونيو 2036 (تقديري)
أول نشر8 أبريل 2026 (فعلي)
آخر تحديث10 نوفمبر 2026
النتائج منشورةغير مذكور في سجل السجل
آخر تأكيد للحالةنوفمبر 2026

فعلي يعني أن الحدث وقع. تقديري يعني أن الجهة الراعية تتوقعه. للكلمتين معنيان مختلفان.

المواقع

12 موقعاً قيد التجنيد

United States

United States
المنشأةالمدينةالولاية أو المنطقةالحالة
Medical University of South CarolinaCharlestonSouth Carolinaقيد التجنيد
The Christ HospitalCincinnatiOhioقيد التجنيد
Henry Ford HospitalDetriotMichiganقيد التجنيد
Minneapolis Heart InstituteMinneapolisMinnesotaقيد التجنيد
Intermountain Medical CenterMurrayUtahقيد التجنيد
Banner HealthPhoenixArizonaقيد التجنيد
Oregon Health and Science UnversityPortlandOregonقيد التجنيد
Mayo ClinicRochesterMinnesotaقيد التجنيد
Sutter Health/ California Pacific Medical CenterSan FranciscoCaliforniaقيد التجنيد
Kaiser Permanente San FranciscoSan FranciscoCaliforniaقيد التجنيد
Honor HealthScottsdaleArizonaقيد التجنيد
Ascension Via Christi HospitalWichitaKansasقيد التجنيد

مستندات الدراسة

لا تُرتبط أي مستندات في سجل السجل هذا.

التغيّرات عبر الزمن

  1. 10 نوفمبر 2026

    تغيّر هدف التجنيد

    Enrollment target revised down from 730 to 520

    730520

  2. 10 نوفمبر 2026

    أُضيف موقع

    11 sites added (12 total)

    112

  3. 17 أغسطس 2026

    تغيّرت الحالة

    Status changed from Not yet recruiting to Recruiting

    NOT_YET_RECRUITINGRECRUITING

  4. 17 أغسطس 2026

    فُتح التجنيد

    Recruitment opened

    NOT_YET_RECRUITINGRECRUITING

  5. 17 أغسطس 2026

    أُضيف موقع

    1 site added (1 total)

    01